Dermavant highlights new data from tapinarof Phase III PSOARING 3 trial

Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has announced Phase III PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults.

The data, from prespecified endpoints of the Phase III PSOARING 3 long-term extension study, are being presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, held March 25-29 in Boston.

“Plaque psoriasis is often a lifelong condition that can have a significant negative impact on many aspects of a patient’s life. Due to limitations in current psoriasis therapies, there is a strong need for new topical treatments for adults suffering with this condition,” said Dr April Armstrong, a dermatologist with Keck Medicine of USC and Professor of Dermatology and Associate Dean for Clinical Research in Dermatology at the Keck School of Medicine of USC. “The durable improvements demonstrated by tapinarof in PSOARING 3 across efficacy outcomes, quality of life and tolerability scores are encouraging. As a clinician, I am excited about the possibility of a potential new therapy in tapinarof for patients suffering from plaque psoriasis,” she added.